Article Text

Download PDFPDF
BET 4: Management of adult patients with icatibant in hereditary angioedema


A short-cut review was carried out to establish whether icatibant is effective in the treatment of hereditary angioedema. A total of 168 papers were found using the reported search, of which one represented the best evidence to answer the clinical question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of this best paper are tabulated. The clinical bottom line is there is promising evidence for the use of the bradykinin receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema.

  • Research
  • epidemiology
  • cardiac care
  • airway
  • eyes
  • major incident planning
  • ECG
  • rsi
  • major incidents
  • acute medicine other
  • education

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Provenance and peer review Commissioned; internally peer reviewed.